» Articles » PMID: 9665969

Comparison of Inflammatory Events During Developing Immunoglobulin E-mediated Late-phase Reactions and Delayed-hypersensitivity Reactions

Overview
Date 1998 Jul 17
PMID 9665969
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

To compare cellular and mediator responses in early developing late-phase skin reactions (LPR) and delayed-hypersensitivity (DH) reactions in the same subjects, responses in skin chambers overlying sites of challenge with pollen antigen and Candida albicans antigens were compared in six humans with demonstrated prominent LPR and DH responses. Histamine levels in overlying chamber fluids at 1 h were much higher at LPR than at DH sites (P = 0.002). After the next 4 h, leukocyte exudation was higher at LPR than at DH sites (P = 0.005). Most leukocytes were activated neutrophils with greater frequency of superoxide-secreting cells and released lactoferrin at LPR than at DH sites (P = 0.01 and P = 0.02, respectively). The frequency of exuding eosinophils was higher, but not significantly so (P = 0.5), at LPR sites. Although significantly more eosinophils at LPR sites were activated (P = 0.02), the levels of released eosinophilic cationic protein were not significantly higher at LPR sites (P = 0.09). The levels of interleukin-8 (IL-8), but not IL-6, were greater at LPR than at DH sites. During the first 5 h of challenge there was greater mast cell activation and subsequent exudation of activated neutrophils at sites of developing LPR than at DH sites, possibly related to greater local IL-8 levels. The frequency of activated eosinophils was also greater at LPR sites. These different initial inflammatory responses could play a role in determining expression of LPR or DH reactions.

Citing Articles

Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective.

Kan A, Tang W, Li P Heliyon. 2024; 10(9):e30553.

PMID: 38726130 PMC: 11079302. DOI: 10.1016/j.heliyon.2024.e30553.


The tripeptide feG regulates the production of intracellular reactive oxygen species by neutrophils.

Mathison R, Davison J J Inflamm (Lond). 2006; 3:9.

PMID: 16776845 PMC: 1534017. DOI: 10.1186/1476-9255-3-9.

References
1.
Vowels B, Rook A, Cassin M, Zweiman B . Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late-phase reactions. J Allergy Clin Immunol. 1995; 96(1):92-6. DOI: 10.1016/s0091-6749(95)70037-4. View

2.
Kaplan A, Kuna P, Reddigari S . Chemokines as allergic mediators--relationship to histamine-releasing factors. Allergy. 1994; 49(7):495-501. DOI: 10.1111/j.1398-9995.1994.tb01119.x. View

3.
Lee C, Neuland M, Teaford H, Villacis B, Dixon P, Valtier S . Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J Allergy Clin Immunol. 1992; 89(5):1010-20. DOI: 10.1016/0091-6749(92)90224-p. View

4.
Charlesworth E, Hood A, Soter N, Norman P, Lichtenstein L . Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest. 1989; 83(5):1519-26. PMC: 303856. DOI: 10.1172/JCI114047. View

5.
Zweiman B, Atkins P, Moskovitz A, von Allmen C, Ciliberti M, Grossman S . Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. J Allergy Clin Immunol. 1997; 100(3):341-7. DOI: 10.1016/s0091-6749(97)70247-1. View